Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.59 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | RARB | P10826 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.59 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288003 | 1.00 | PTGS2 (0.63) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL892055 | 1.00 | PTGS2 (0.63) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL9232479 | 0.98 | PTGS2 (0.61) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| Hydrochloric Acid SCHEMBL28716582 | 0.98 | PTGS2 (0.61) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL9232475 | 0.98 | PTGS2 (0.61) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL9234136 | 0.98 | PTGS2 (0.61) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL1678786 | 0.94 | PTGS2 (0.74) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| Butane SCHEMBL27363299 | 0.92 | PTGS2 (0.56) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL59197 | 0.90 | PTGS2 (0.74) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL4255166 | 0.90 | LMNA (0.58) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49351-E1 | Cytoprotective agent | BIOGEN MA INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA UNIVERSITY (JP) | 2021-01-07 | — | — | US | disclosed |
| CN-111471663-A | Method for immobilizing pseudomonas fluorescens lipase by using metal organic framework material | 湖南理工学院 | 2020-07-31 | — | — | CN | disclosed |
| CN-111471663-A | Method for immobilizing pseudomonas fluorescens lipase by using metal organic framework material | 湖南理工学院 | 2020-07-31 | — | — | CN | disclosed |
| US-RE47684-E1 | Cytoprotective agent | TMS CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| US-9078880-B2 | Cytoprotective agent | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9078880-B2 | Cytoprotective agent | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2015-07-14 | — | — | US | disclosed |
| US-8883462-B2 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-1806342-B1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8063242-B2 | for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion | DOMPE PHA.R.MA S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| EP-2229942-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| EP-2229942-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| EP-1455773-B1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-04 | — | — | EP | disclosed |
| CN-100376242-C | 2-aryl-propionic acid and medicine composition containing same | DOMPAY CO LTD (IT) | 2008-03-26 | — | — | CN | disclosed |
| CN-1612729-A | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPAY CO LTD (IT) | 2005-05-04 | — | — | CN | disclosed |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2005-02-17 | — | — | US | disclosed |
| EP-1455773-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003043625-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-05-30 | — | — | WO | disclosed |
| EP-0673924-A1 | PROPIONIC ACID DERIVATIVE | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | PTGS2 142/4885PTGS1 74/4885AKR1C3 1134/4885 |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | REN, ATP6V1B1, SLC10A1 | PTGS2 147/4885PTGS1 97/4885AKR1C3 1381/4885 |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | CXCR2, FPR1, CCR2 | PTGS2 99/4885PTGS1 88/4885AKR1C3 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.